Can Rhinomed help the world get a good night’s sleep?

Trial results months away for doc who treated himself with cancer drug

First published on STOCKHEAD – July 26th, 2017



ot many medical researchers have more incentive than Dr Graham Kelly.

While working to develop drugs that make cancer treatments work better, the 71-year-old developed prostate cancer himself.

After exhausting all treatment options, Dr Kelly decided to take a chance on his own experimental drug – which had only ever worked in the laboratory.

“I was facing death — there’s no other way of putting it,’’ he later told Tim Boreham in The Australian.

The cancer-surviving doc was then the CEO of Novogen (ASX:NRT), a biotech group once worth $800 million.

These days Novogen is worth around $20 million and Dr Kelly continues his research with new drug developer, Noxopharm (ASX:NOX), which listed last year in a $6 million Initial Public Offering.

The drug, known these days as NOX66, works in conjunction with current chemotherapy drugs and radiation therapy which targets the source of a cancer.

Noxopharm, currently promoting NOX66 on a roadshow through Singapore and Hong Kong, plans to report on initial trial results before Christmas – and have a drug on the market within five years.

“We expect to know by end of 2017 of the success of our mission,” the company reported this month in its roadshow presentation.

“We aim to be in a registration study by end of 2018 [and] to have marketing approval by 2022.”

Registration studies are completed with regulators such as the US Food and Drug Administration as a precursor to market approval…